October 26, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Mikasa Seiyaku to Dissolve Partnership with Chugai Pharmaceutical
 

Tokyo, Dec 9, 2004 (JCN) - Mikasa Seiyaku has announced that it has mutually agreed with Chugai Pharmaceutical (TSE: 4519) to dissolve their partnership as of December 29.

For the past 10 years, the two companies have collaborated in over-the counter (OTC) drug business. In response to the latest transfer of Chugai's OTC business to Lion, the two companies have come to this decision.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Chugai News  
  Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent  (Jan 9, 2013)
  Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial  (Dec 16, 2008)
  DATA from Overseas Phase III Trial of "Actemra" a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients  (Oct 27, 2008)
  Roche to Raise Chugai Pharm Stake to 59.9 Percent  (May 23, 2008)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)